UK pharmacist says Eli Lilly’s Mounjaro price hike a “shock”
Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald…
Metabolic Disorders
-
-
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors…
-
WeightWatchers shuns compounded semaglutide amid FDA rules
WeightWatchers has confirmed it no longer offers compounded semaglutide, instead providing patients with Novo Nordisk’s branded drug Wegovy. In its…
-
Novo Nordisk’s diabetes and weight loss drug sales growth decelerates
Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming…
-
Novo Nordisk teams up with WeightWatchers in latest telehealth push
Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with…
-
Why can’t the US figure out weight loss drug prices?
“I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They…
-
Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug
Novo Nordisk has terminated a collaboration agreement with Hims & Hers, accusing the telehealth company of "failing to adhere to…
-
Madrigal poised to enter European MASH market after CHMP endorsement
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after…
-
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients…
-
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m…
